These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26922914)

  • 1. Systemic therapy for metastatic bladder cancer in 2016 and beyond.
    Collazo-Lorduy A; Galsky MD
    Future Oncol; 2016 May; 12(9):1179-92. PubMed ID: 26922914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.
    Ortmann CA; Mazhar D
    Future Oncol; 2013 Nov; 9(11):1637-51. PubMed ID: 24156324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and therapeutic applications of the molecular events in clinical management of urothelial carcinoma of bladder.
    Garg M
    J Exp Ther Oncol; 2014; 10(4):301-16. PubMed ID: 25509986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging drugs for urothelial (bladder) cancer.
    Cumberbatch K; He T; Thorogood Z; Gartrell BA
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting.
    Gallagher DJ; Milowsky MI; Bajorin DF
    Cancer; 2008 Sep; 113(6):1284-93. PubMed ID: 18629841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future directions and targeted therapies in bladder cancer.
    Sonpavde G; Jones BS; Bellmunt J; Choueiri TK; Sternberg CN
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):361-76, x. PubMed ID: 25836940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise.
    Zachos I; Konstantinopoulos PA; Tzortzis V; Gravas S; Karatzas A; Karamouzis MV; Melekos M; Papavassiliou AG
    Expert Opin Investig Drugs; 2010 Jul; 19(7):875-87. PubMed ID: 20528482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinflunine in the treatment of advanced bladder cancer.
    Mamtani R; Vaughn DJ
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):13-20. PubMed ID: 21166506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular biology and targeted therapies for urothelial carcinoma.
    Seront E; Machiels JP
    Cancer Treat Rev; 2015 Apr; 41(4):341-53. PubMed ID: 25828962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current treatment of metastatic bladder cancer and future directions.
    Lei AQ; Cheng L; Pan CX
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1851-62. PubMed ID: 22117153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drugs for urothelial carcinoma.
    Gartrell BA; Sonpavde G
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):477-94. PubMed ID: 24195728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Options in metastatic urothelial cancer after first-line therapy.
    Alimohamed NS; Sridhar SS
    Curr Opin Support Palliat Care; 2015 Sep; 9(3):255-60. PubMed ID: 26262830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of advanced bladder cancer in the era of targeted therapies.
    Soave A; Engel O; Von Amsberg G; Becker A; Dahlem R; Shariat SF; Fisch M; Rink M
    Minerva Urol Nefrol; 2015 Jun; 67(2):103-15. PubMed ID: 25604695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer.
    Rossi L; Santoni M; Crabb SJ; Scarpi E; Burattini L; Chau C; Bianchi E; Savini A; Burgio SL; Conti A; Conteduca V; Cascinu S; De Giorgi U
    Ann Surg Oncol; 2015 Apr; 22(4):1377-84. PubMed ID: 25234022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer: diagnostic, biological and prognostic aspects.
    Davidson B; Tropé CG
    Womens Health (Lond); 2014 Sep; 10(5):519-33. PubMed ID: 25335543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
    Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
    Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platinum-based chemotherapy for bladder cancer.
    Waxman J; Wasan H
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):54-60. PubMed ID: 7992067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy for urothelial cancer of the bladder--update 2012].
    Niegisch G; Lorch A; Albers P
    Aktuelle Urol; 2012 Dec; 43(6):412-9. PubMed ID: 23196781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal treatment for metastatic bladder cancer.
    Carballido EM; Rosenberg JE
    Curr Oncol Rep; 2014 Sep; 16(9):404. PubMed ID: 25056737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group.
    Galsky MD; Hendricks R; Svatek R; Bangs R; Hoffman-Censits J; Clement J; Dreicer R; Guancial E; Hahn N; Lerner SP; O'Donnell PH; Quale DZ; Siefker-Radtke A; Shipley W; Sonpavde G; Vaena D; Vinson J; Rosenberg J
    Cancer; 2013 Jun; 119(11):1994-8. PubMed ID: 23456777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.